IntoCell인투셀
287840 · KOSDAQ · ₩287840 · 인투셀
- Market cap
- ₩240B
- Enterprise value
- ₩239B
- P/E
- —
- P/B
- 12.2×
- Dividend yield
- 0.0%
- ROE
- −44.8%
- Net margin
- −275.9%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−78.7% from the high
₩13,050Today: ₩15,720 – ₩16,490₩74,900
Returns
- 1W−5.8%
- 1M−8.6%
- 3M−3.2%
- 6M−59.3%
- YTD−72.2%
- 1Y−68.0%
- Volume today
- 22,757
- 0.6× the 20-day average
- Traded today
- ₩366M
- Listed shares
- 15,021,960
- EPS (12 months)
- −₩586
- Earnings yield −3.7%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 40 of 100 (50 is a normal day for this stock).
- MomentumWeak-6.5% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
IntoCell stock overview
IntoCell (인투셀, KRX: 287840) is listed on KOSDAQ, in the Biotech & Pharma sector. InTheCell is a Korean ADC platform technology company that researches and develops linkers and payloads for antibody-drug conjugates (ADCs). Its shares closed at ₩15,980 on Oct 27, 2026, down 0.75% on the day, giving it a market value of ₩240B.
Key facts
- Market cap
- ₩240B
- Sector
- Biotech & Pharma
- Latest price change
- −0.75%
- As of
- Oct 27, 2026
- Main business
- InTheCell is a Korean ADC platform technology company that researches and develops linkers and payloads for antibody-drug conjugates (ADCs).
Quick answers about IntoCell
- What does IntoCell do?
- InTheCell is a Korean ADC platform technology company that researches and develops linkers and payloads for antibody-drug conjugates (ADCs). Its core technologies include the OHPAS cleavable linker platform and the PMT platform for improving payload selectivity, along with proprietary payload technologies. The company earns revenue mainly by out-licensing its platform technologies and preclinical or early-clinical drug candidates to global pharmaceutical companies, and its lead candidate, an anti-B7-H3 ADC (ITC-6146RO), has received IND approvals in Korea and the United States.
- What is the market cap of IntoCell?
- The market capitalisation of IntoCell was ₩240B at the close on Oct 27, 2026.
- Who are the largest shareholders of IntoCell?
- According to the latest official filings, the largest reported holders are Park Tae-gyo (19.77%, as of Jul 16, 2025); Orbit-Brave New No. 1 New Technology Business Investment Partnership (4.80%, as of Jun 23, 2025); ATINUM Investment (4.77%, as of May 30, 2025).
- When is the next earnings report from IntoCell?
- Korean companies rarely announce results dates in advance. Based on when IntoCell filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own IntoCell?
- Yes. The National Pension Service held 1.04% of IntoCell shares as of Dec 31, 2025.
Company profile
InTheCell is a Korean ADC platform technology company that researches and develops linkers and payloads for antibody-drug conjugates (ADCs). Its core technologies include the OHPAS cleavable linker platform and the PMT platform for improving payload selectivity, along with proprietary payload technologies. The company earns revenue mainly by out-licensing its platform technologies and preclinical or early-clinical drug candidates to global pharmaceutical companies, and its lead candidate, an anti-B7-H3 ADC (ITC-6146RO), has received IND approvals in Korea and the United States.
Written by AI from the company's latest annual report.
- Korean name
- 인투셀
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 박태교
- Founded
- Apr 2015
- Listed
- May 2025
- Listed shares
- 15,021,960
- Fiscal year ends
- Month 12
- Website
- intocell.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Investor relations (IR) eventAug 18, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Major management matter relevant to investorsJul 22, 2026
- Insider shareholding reportJun 5, 2026
- Insider shareholding reportJun 5, 2026
Titles in Korean until English translations are added.
Also known as: IntoCell / 인투셀 / 287840 / KRX:287840
Source: KRX statistical information